EspeRare's ER-004 Receives the US FDA's Breakthrough Therapy Designation for Prenatal Treatment of XLHED
Shots:
- The BT designation is provided on three results from three XLHED subjects with a course of ER-004 intra-amniotic injections during the third trimester of pregnancy while the results were published in NEJM and showed profound and life-changing effects on infants
- The US FDA’s BT designation is granted to expedite the development and review of drugs for serious or life-threatening conditions allowing the program to benefit from all the FDA's fast-track program feature
- In H2’21- EspeRare to enroll patients for the study which is also benefited with Fast Track and ODD and has also received the EMA’s PRIME designation and ODD
Click here to read full press release/ article | Ref: PRNewswire | Image: PharmaWorld
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com